OncoMatch/Clinical Trials/NCT07112196

Visugromab in Cachexia International Trial

Is NCT07112196 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Visugromab (CTL-002) and Visugromab (CTL-002) for cancer-associated cachexia.

Treatment: Visugromab (CTL-002) · Visugromab (CTL-002) · Visugromab (CTL-002) — A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.